Welcome to our dedicated page for Adia Nutrition news (Ticker: ADIA), a resource for investors and traders seeking the latest updates and insights on Adia Nutrition stock.
Adia Nutrition Inc. (ADIA) operates at the intersection of advanced regenerative medicine and premium nutritional science. This centralized news hub provides investors and healthcare professionals with essential updates on the company's dual focus: organic supplement innovations and groundbreaking stem cell therapies.
Access timely announcements spanning regulatory milestones, clinical trial progress, and strategic partnerships. Key updates include FDA compliance developments, treatment protocol validations, and distribution network expansions through Adia Labs LLC. Our curated feed ensures transparent tracking of financial audits and operational enhancements as the company progresses toward OTCQB listing.
Bookmark this resource for verified updates on autologous stem cell treatments for multiple sclerosis, umbilical cord therapy advancements, and nutritional product line extensions. Regular monitoring recommended for stakeholders tracking healthcare innovation in regulated markets.
Adia Nutrition Inc. (OTC Pink: ADIA) has filed for uplisting to the OTCQB Venture Market following a successful independent audit with Astra Audit and Advisory on April 1, 2025. The company specializes in regenerative medicine and nutritional wellness, focusing on stem cell therapies and nutritional products.
As part of the uplisting process, OTC Markets will handle Adia's Form 15c2-11, streamlining the broker-dealer quotation process and enhancing transparency. The company has also requested the Non-Objecting Beneficial Owners (NOBO) list to improve direct shareholder communication.
CEO Larry Powalisz emphasized that these strategic moves align with the company's commitment to transparency and growth. The uplisting is part of Adia's broader roadmap toward a potential Nasdaq Small Cap listing, aiming to enhance market credibility and expand its investor base while continuing to develop its clinic network and regenerative medicine solutions.
Adia Nutrition Inc. (OTC Pink: ADIA) has successfully completed an independent audit with Astra Audit and Advisory , a PCAOB-registered auditing firm, positioning the company for uplisting to the OTCQB market. This milestone represents a significant step toward enhanced transparency and investor confidence.
The company, focused on advanced stem cell therapies and nutritional wellness, provides cutting-edge treatments including Umbilical Cord Stem Cell (UCB-SC) treatments and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) nationwide. The planned uplisting to OTCQB is expected to provide greater liquidity and market exposure, supporting the company's expansion of its clinic network and development of innovative therapies for conditions like Multiple Sclerosis.
Adia Nutrition (OTC Pink: ADIA) has announced a significant court ruling ordering the cancellation of over 25 million shares, including more than 15 million restricted common shares and 10 million preferred shares. This decision will reduce the company's outstanding shares by over 15 million.
The company has already contacted the transfer agent to initiate the share cancellation process. According to CEO Larry Powalisz, this reduction in outstanding shares is expected to increase the value of remaining shares by concentrating ownership and improving earnings per share metrics, directly benefiting current investors.
The company anticipates additional strategic initiatives in the near future as it continues to operate in the nutrition and wellness sector.
Adia Nutrition Inc. (OTC Pink: ADIA) has announced the opening of its first satellite location in Tinton Falls, New Jersey, through a strategic shared space agreement with Keep Glowing Medical Spa and Dr. Michael Ellis. The facility will operate under Adia Med, offering FDA-compliant regenerative treatments including AdiaVita and AdiaLink.
The location will provide stem cell therapies targeting inflammation, autoimmune disorders, and musculoskeletal issues. AdiaVita contains 100 million viable cells and 3 trillion exosomes per unit, while AdiaLink offers 3.5 trillion exosomes per unit. These products meet Section 361 of the Public Health Service Act standards.
This expansion follows the launch of Adia's flagship clinic in Winter Park, Florida, in January 2025. The partnership model reduces overhead costs while accessing an established patient base, serving as a template for future nationwide expansion in the $15.1 billion global stem cell market.
Adia Nutrition (OTC Pink: ADIA) has announced that its subsidiary, Adia Med, is exploring international expansion following significant interest from global healthcare entities. The company has received legal confirmation supporting its ability to operate clinics abroad and is evaluating a specific location outside the US for its first international facility.
The expansion focuses on delivering advanced treatments including Therapeutic Plasma Exchange (TPE), Hematopoietic Stem Cell Transplantation (HSCT), and umbilical cord blood stem cell therapies using their premier product, Adia Vita. Adia Med is currently one of only three clinic networks in the US offering this specialized technology.
The company is now conducting a comprehensive review of international regulations and requirements while developing strategic partnerships to facilitate market entry. The move aims to extend access to Adia Vita's regenerative medicine treatments, which have gained recognition for their potency and purity in treating various conditions from circulatory disorders to orthopedic applications.
Adia Med (OTC Pink: ADIA) is spearheading an initiative to standardize umbilical cord stem cell use across the United States. The company plans to present pioneering standards to the Department of Health and Human Services and FDA, addressing widespread inconsistencies in stem cell therapies.
The initiative focuses on four key pillars:
- Homologous Use Standards to ensure stem cells are used according to natural functions
- Quality Control Protocols for harvesting, processing, and storage
- Mandatory Third-Party Verification of stem cell count and viability
- Best Practices Development through collaboration with experts
The company aims to combat the rising problem of substandard or non-viable stem cells being provided to patients. Under the proposed standards, every stem cell batch would require third-party verification certificates confirming quantity and viability, ensuring transparency and accountability in the industry.
Adia Nutrition (OTC: ADIA) has announced that its subsidiary, Adia Med, will incorporate Therapeutic Plasma Exchange (TPE) treatment across all future full clinic locations in the United States, with its current location already offering this service. TPE uses apheresis machines to remove and replace patient plasma, targeting harmful substances in the bloodstream.
The clinics will utilize the same equipment used for Hematopoietic Stem Cell Transplantation (HSCT), making Adia Med one of only three clinic networks in the U.S. with this technology. The treatment shows promise for various conditions, including Alzheimer's disease, where studies indicate TPE combined with albumin replacement can slow cognitive decline.
The national average cost for TPE ranges from $4,000 to $6,000 per patient. With Florida's large retiree population of over 4.5 million residents aged 65 and older, Adia Med sees significant market potential, particularly for age-related conditions and autoimmune disorders.
ADIA Nutrition Inc. (OTC Pink: ADIA) has launched a recruitment drive for sales representatives for its subsidiaries, Adia Med and Adia Labs. The initiative, announced on March 13, 2025, aims to expand the company's regenerative medicine and stem cell therapy presence nationwide.
Adia Med sales representatives will focus on establishing satellite locations by partnering with doctors, clinics, and medical spas, targeting regions with high demand for regenerative medicine. Meanwhile, Adia Labs representatives will promote 'Adia Vita,' a private-label umbilical cord stem cell product containing 100 million stem cells and 3 trillion exosomes per unit, for medical studies and research.
The company offers commission-based compensation and comprehensive training. Ideal candidates should possess strong communication skills, commitment to ethical practices, and knowledge or willingness to learn about regenerative medicine.
ADIA Nutrition Inc. (OTC Pink: ADIA) has announced strategic workforce expansions to enhance its operations and advance regenerative medicine capabilities. The company has hired a skilled intake nurse at their Winter Park Clinic who will manage patient intake, assist with assessments, and develop compliance standards for stem cell treatments across all Adia Med locations.
Additionally, the company has promoted a three-year intern to serve as CEO Larry Powalisz's aide, taking over marketing efforts, social media strategy, and various projects to allow the CEO to focus on broader company expansion initiatives.
These strategic hires follow ADIA Nutrition's recent achievements, including the profitable launch of the Adia Med Winter Park Clinic and plans for nationwide expansion. The new positions are expected to enhance operational efficiency, ensure scalable care standards, and strengthen the company's position in delivering regenerative therapies.
ADIA Nutrition Inc. (OTC Pink: ADIA) has filed trademark applications with the USPTO for its new product 'Adia Vita' and slogan 'The Platinum Standard in Stem Cell Therapy.' The company's new private-label umbilical cord stem cell product, Adia Vita, features third-party-verified content of 100 million stem cells and 3 trillion exosomes per unit.
The product is now available for purchase through Adia Labs to doctors and clinics for trials and research. According to CEO Larry Powalisz, these trademark filings aim to protect the brand from copycats and ensure product authenticity in the regenerative medicine market.
